Addressing the Challenges of Monoclonal Antibody Manufacturing and Cell Line Optimization
SAMP8 (senescence-accelerated mouse [SAM]-prone line 8) is a well-studied model that has proven valuable for studying age-related cognitive decline and sarcopenia. But after ~40 years of line maintenance, questions have emerged about the model’s consistency and reliability. Does SAMP8 still exhibit its canonical phenotypes? Has the SAMP8 line experienced genetic drift?
Researchers at Inotiv wanted to determine whether SAMP8 mice can continue to reliably support senescence-related studies in learning, memory, cognition, and muscle physiology. This article shares findings from Inotiv’s in-depth internal validation study.
A Brief Background on SAMP8 Mice
The SAMP8 strain was selectively bred to express accelerated senescence phenotypes, meaning the model naturally exhibits many aging-related characteristics without the complications sometimes seen in transgenic mice.
The key areas of interest in SAMP8—sarcopenia and cognitive decline—can be observed as early as six to nine months of age. This capability is especially important for researchers seeking to evaluate therapeutic interventions efficiently, without waiting for animals to naturally display senescent changes at 2 years of age. For example, SAMP8 mice display robust aging-related phenotypes at 8–10 months of age, whereas normal mice would take 18+ months to express them. This efficiency translates into faster go/no-go decisions and more actionable preclinical data to support biotech and pharma clients.
Study Methods
Inotiv compared 24 SAMP8 mice (12 male, 12 female) with the control: 24 SAM-resistant (SAMR1) mice (12 males, 12 females). The animals were aged 24 weeks before behavioral assessments took place. Weekly body weights and clinical observations, as well as age-related behaviors, were assessed through the study. Necropsy was performed at 38-weeks-old with histopathology on muscle tissues and cochleae.
SAMP8 Observations
At a high level, a 60 SNP panel showed no evidence of genetic drift. SAMP8 mice displayed accelerated aging phenotypes compared to the SAMR1 control mice, but a few findings were unexpected.
Anxiety-like behaviors were variable: In locomotion and anxiety assessments, SAMP8 mice showed increased activity and anxiety in the open field, increased activity in the Y-maze, but reduced anxiety in the elevated plus maze (EPM). Reports conflict on the direction of anxiety-like phenotypes in both assays.
Expected muscle weakness and loss of motor coordination were demonstrated: In the rotarod, grip strength, wire hang, and parallel rod floor tests, SAMP8 mice were consistently impaired.
Muscle inflammation and sarcopenia were observed: Histopathology data showed evidence of sarcopenia phenotypes in SAMP8 mice with reduced muscle fiber diameter and elevated muscle inflammation relative to SAMR1 mice.
Cognitive decline deficits were observed, but slightly varied from published reports:
Spatial learning and memory aligned with reports:
SAMP8 mice demonstrated intact learning but had motor difficulties. As expected, SAMP8 mice had impaired short-term spatial memory and a deficit in long-term spatial memory in the Morris water maze.
Spatial and auditory associative memory differed from reports:
Published reports show that SAMP8 mice demonstrate deficits in contextual fear conditioning, but Inotiv did not observe significant differences between SAMP8 and SAMR1 mice in either the contextual or cued fear conditioning tests.
Working memory differed from reports:
Published reports show SAMP8 mouse deficits in the Y-maze; however, in this study, SAMP8 mice displayed increased working memory in the Y-maze.
Hearing loss was not observed: No auditory deficits were observed in startle testing, and histopathology did not reveal any differences in cochlear or auditory nerve degeneration or inflammation.
Weight gain was unexpected: SAMP8 mice gained more weight over time than SAMR1 mice, contrary to expectations.
By sharing this validation data, Inotiv can better support researchers in designing studies with realistic expectations and help improve study success rates.
Ongoing Studies in SAMP8
Inotiv is focusing on further characterization of SAMP8 brain neurodegeneration and inflammation using advanced immunofluorescence techniques in the cortex and hippocampus. In parallel, senescence in the hippocampus is being evaluated using double immunofluorescence for the senescence marker p16 and the neuronal progenitor marker SOX2, providing deeper insight into cellular aging processes in key cognitive regions.
Supporting Senescence Studies from Design to Execution
The SAMP8 model exemplifies how accelerated aging, combined with comprehensive CRO support, can help streamline preclinical research, reduce time and costs, and provide high-quality, reproducible data. For sponsors exploring sarcopenia, cognitive decline, or other age-related phenotypes, our integrated approach at Inotiv enables faster insights, more confident decision-making, and a stronger foundation for translating findings into clinical research.